Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Evolution of Effectiveness of Diabetes Medical Care in Russia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Lyen an sove nan clipboard la
EstatiKonplete
Patwone
Endocrinology Research Centre, Moscow

Mo kle

Abstrè

The main aim of the present study is to evaluate the prevalence of individual microvascular and macrovascular complications among diabetes mellitus patients and to determine the percentage of diabetes mellitus patients achieved HbA1c<7,0%.

Deskripsyon

Rationale for this Study Primary Existing routine health statistics underestimates the rate of morbidity due to diabetes complications. To provide more realistic estimation of morbidity, repeated epidemiological studies are essential in assessment of tendencies in diabetes medical care at the country level. They allow to reveal issues, which, being resolved, can contribute to the improvement of diabetes medical care effectiveness. Guidelines developed with this study data may save healthcare budgets and prevent financial losses due to diabetes-related morbidity and disability.

Objectives of the Study • Primary objective: To determine the prevalence of individual microvascular and macrovascular complications among patients with diabetes mellitus type 1 and type 2

• Secondary objective: To determine the percentage of patients with diabetes mellitus type 1 and type 2 achieved HbA1c <7,0%.

Study design The hired medical team (9 specialists) is going to perform the technical study-related tasks in Moscow Region.

Target population includes approximately 147,000 diabetes mellitus patients included in Regional Diabetes Mellitus Register, from which patients will be selected via random sampling (600 patients).

A special rented medical bus will accommodate the study personnel at the place and all the local study-related activities.

After obtaining a written Informed Consent Form by local endocrinologist the each study subject will have one study visit, when he or she should appear fasting and the following data will be collected, tests and examination performed:

- date of the diagnosis of type 1 or type 2 diabetes mellitus;

- medical history including coronary heart disease, myocardial infarction, coronary revascularization, cerebrovascular disease (ischaemic stroke, a transient ischemic attack), peripheral artery disease, diabetic retinopathy (type, stage, year of diagnosis), diabetic neuropathy, chronic kidney disease, diabetic foot;

- blood tests for HbA1c, serum total cholesterol, triglycerides, HDL- cholesterol, serum creatinine and estimation estimated Glomerular filtration rate by standard CKD-EPI, alanine-aminotransferase, aspartate-aminotransferase;

- urine analysis for albumin in spot urine;

- measurement of height, weight/BMI;

- measurement of sitting blood pressure, Electocardiogramm;

- eye examination, including fundoscopy;

- foot examination, including tests for touch, pain, temperature, and vibration sensation of the toes and mini-doppler ultrasound vessel study;

- current pharmacological therapy regimen (medications, daily doses). The medical team will admit up to 35 study subjects per day. This study has descriptive character. There is no any comparison to be performed.

Dat

Dènye verifye: 03/31/2016
Premye Soumèt: 12/17/2014
Enskripsyon Estimasyon Soumèt: 10/08/2015
Premye afiche: 10/11/2015
Dènye Mizajou Soumèt: 04/04/2016
Dènye Mizajou afiche: 04/05/2016
Dat aktyèl kòmanse etid la: 07/31/2015
Dat Estimasyon Prensipal Estimasyon an: 09/30/2015
Dat estime fini etid la: 09/30/2015

Kondisyon oswa maladi

Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Faz

-

Kritè kalifikasyon yo

Laj ki kalifye pou etid 18 Years Pou 18 Years
Sèks ki kalifye pou etidAll
Metòd echantiyonajNon-Probability Sample
Aksepte Volontè HealthyWi
Kritè

Inclusion criteria:

The subject population for this study must meet the following criteria:

1. Provision of singed subject informed consent

2. Type 1 and type 2 diabetes mellitus Target population includes approximately 147,000 diabetes mellitus patients included in Regional DM Register, from which patients will be selected via random sampling (600 patients).

The prescription of the medicinal product is clearly separated from the decision to include the subject in the study.

Exclusion criteria:

1. Diagnosis of gestational diabetes mellitus alone.

Rezilta

Mezi Rezilta Prensipal yo

1. Percentage of patients with diabetes mellitus type 1 and type 2diabetes mellitus complications [30 days]

macrovascular complications, i.e. with history of chronic heart disease myocardial infarction ischaemic stroke transient ischemic attack any revascularization procedure any peripheral atherosclerosis e) microvascular complications, i.e. diabetic retinopathy diabetic neuropathy albuminuria chronic kidney disease stage f) other complications diagnosed after diabetes mellitus has been established, i.e. foot examination findings

Mezi Rezilta Segondè

1. The percentage of patients with diabetes mellitus type 1 and type 2 achieved HbA1c <7% [30 days]

2. Structure of antidiabetic therapy (% insulin, % OAD mono, % OAD dual, % OAD triple) [30 days]

Antre nan paj
facebook nou an

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

  • Travay nan 55 lang
  • Geri èrbal te apiye nan syans
  • Remèd fèy rekonesans pa imaj
  • Kat entèaktif GPS - tag zèb sou kote (vini byento)
  • Li piblikasyon syantifik ki gen rapò ak rechèch ou an
  • Search remèd fèy medsin pa efè yo
  • Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye

Google Play badgeApp Store badge